華大基因(300676.SZ):已與NUPCO簽訂第二次延期協議 其追加了約1.38億美元合同
格隆匯7月5日丨華大基因(300676.SZ)公佈,截至公吿披露日,公司已累計收到NUPCO支付的上述合同款項金額為328,068,293美元。鑑於沙特阿拉伯當地疫情防控的需要,NUPCO需繼續增加新冠病毒檢測綜合解決方案相關的採購,近日,公司全資子公司香港醫學已與NUPCO簽訂了《第二次延期協議》,原合同的履行期限延長至2021年12月25日。
此次簽署的《第二次延期協議》追加了138,213,412美元的合同金額,如實際項目產生費用與此略有變動,雙方應另行書面約定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.